Amneal Pharmaceuticals (AMRX) presents at 41st Annual J.P. Morgan Healthcare Conference - Slideshow

Financial Performance and Growth Strategy - Amneal reported approximately $2.2 billion in revenue, reflecting the midpoint of the 2022 guidance[5] - The company aims to achieve below 4x net leverage through adjusted EBITDA growth and debt reduction[5] - Amneal projects injectables business to reach over $300 million by 2025, representing a 24%+ CAGR[6] - The company anticipates over $200 million in peak U S sales from the first three biosimilars[6] - Amneal expects $500 million to $1 billion in peak U S sales from the specialty pipeline[6] - Adjusted EBITDA grew at a +15% CAGR from 2019 to 2022[24] Product Portfolio and Pipeline - Amneal has a diverse portfolio of over 250 products[5,10] - The company plans to launch 20-30 new generic products each year[5,6,12,30] - Amneal is developing a pipeline of approximately 106 products with a total addressable market (TAM) of around $45 billion[12] Biosimilars and Injectables - The estimated U S market size for Amneal's first three approved oncology biosimilars is approximately $4 billion[17] - Amneal is targeting 30-40 injectable launches by 2025[13]